Ensysce Biosciences, Inc. (ENSC) - Dilution Analysis

10-Q filing | 14.7M shares outstanding

10-K filing | 9.3M shares outstanding

S-3 filing: This prospectus relates to the issuance and resale of up to 4,599,000 shares of common stock by the company and selling security holders, including shares issuable upon conversion of preferred stock and exercise of warrants.

10-Q filing | 3.5M shares outstanding

10-Q filing | 3.0M shares outstanding

10-Q filing | 2.4M shares outstanding

S-3 filing: The company entered into inducement offer letter agreements with warrant holders and issued unregistered warrants to purchase common stock and issued warrants to a placement agent.

8-K filing: Ensysce Biosciences, Inc. completed a private placement offering involving the issuance of warrants to purchase up to 1,260,752 shares of common stock and warrants to the placement agent to purchase up to 44,126 shares of common stock, generating gross proceeds of approximately $2.2 million. ($2.2M proceeds)

S-3 filing: This S-3 filing registers shares of common stock issuable upon the exercise of warrants, as well as resale of common stock by selling security holders.

S-3 filing: This S-3 filing relates to the issuance and resale of up to 980,000 shares of common stock by the company and selling security holders, as well as a registered direct offering of common stock and pre-funded warrants.

8-K filing: Ensysce Biosciences, Inc. completed a registered direct offering and a concurrent private placement on March 31, 2025, issuing shares of common stock and warrants for gross proceeds of approximately $1.1 million.

10-K filing | 1.4M shares outstanding

8-K filing: Stock split 1-for-15 | Outstanding: 19,574,014 → 1,304,934

10-Q filing | 19.6M shares outstanding

S-3 filing: The filing discusses the issuance of unregistered Series A-3 and A-4 warrants, and warrants to a placement agent, all exercisable for common stock, and the filing of a registration statement for the resale of the common stock issuable upon exercise of these warrants.

POS AM filing: This prospectus relates to the issuance and resale of up to 4,796,478 shares of common stock, consisting of shares issuable upon conversion of notes and exercise of warrants.

8-K filing: Ensysce Biosciences, Inc. entered into a Securities Purchase Agreement for a registered direct offering of common stock and pre-funded warrants, along with related warrants in a private placement, for gross proceeds of approximately $4.5 million, to be used for continued development of its TAAP and MPAR® programs and for working capital. ($1.67M proceeds)

10-Q filing | 8.8M shares outstanding

10-Q filing | 7.6M shares outstanding

POS AM filing: The company entered into a Securities Purchase Agreement for an aggregate financing of $8.0 million with institutional investors and issued warrants to purchase common stock, with the exercise price subsequently reduced.

S-1/A filing: This S-1/A filing relates to the offering of shares of common stock to be issued or potentially issuable upon the exercise of the 2024 Warrants.

10-K filing | 7.3M shares outstanding

8-K filing: Ensysce Biosciences, Inc. closed an offering on February 14, 2024, involving the exercise of existing warrants and issuance of new warrants, resulting in gross proceeds of approximately $4.7 million. ($4.7M proceeds)

S-1 filing: S-1 Filing for Ensysce Biosciences, Inc. on 2024-01-17

RW filing: The company is seeking withdrawal of the registration statement because a portion of the shares to be registered for resale under the Registration Statement may be resold in accordance with Rule 144 and the remainder of the shares to be registered for resale were shares issuable as repayment of the balance of a convertible note, including interest thereon, and other amounts owed, upon conversion of such note and such other amounts owed into shares, which convertible note and such other amounts owed were instead repaid in full with cash in March 2023 and May 2023.

8-K filing: Ensysce Biosciences, Inc. completed a second closing under a Securities Purchase Agreement, issuing notes and warrants for an aggregate purchase price of $1,133,333 and warrants to purchase 2,511,394 shares of common stock.

S-1/A filing: This is an S-1/A filing for Ensysce Biosciences, Inc. registering for resale 6,179,953 shares of common stock by selling securityholders, consisting of shares issuable upon conversion of Investor Notes and exercise of Investor Warrants.

S-1 filing: This is an S-1 filing for Ensysce Biosciences, Inc. regarding the offering of 6,179,953 shares of common stock by Selling Securityholders, consisting of shares issuable upon conversion of Investor Notes and exercise of Investor Warrants.

10-Q filing | 3.1M shares outstanding

8-K filing: Ensysce Biosciences, Inc. entered into a Securities Purchase Agreement for an aggregate financing of $1.7 million with investors, issuing senior secured convertible promissory notes and warrants to purchase common stock. ($3.4M proceeds)

10-Q filing | 2.9M shares outstanding

8-K filing: Ensysce Biosciences, Inc. closed a public offering of 1,800,876 shares of common stock, Series A-1 warrants to purchase up to 1,800,876 shares of common stock and Series A-2 warrants to purchase up to 1,800,876 shares of common stock at a combined public offering price of $3.887 per share, resulting in gross proceeds of approximately $7.0 million before deductions. ($7.0M proceeds)

10-Q filing | 1.3M shares outstanding

POS AM filing: This is a POS AM filing for common stock purchase warrants, as amended May 10, 2023, where Ensysce Biosciences, Inc. is issuing warrants to purchase common stock.

S-1/A filing: This S-1/A filing is for offering up to 2,285,714 shares of common stock and Series A-1 warrants to purchase up to 2,285,714 shares of common stock and Series A-2 warrants to purchase up to 2,285,714 shares of common stock, or pre-funded warrants to purchase shares of common stock and common warrants to purchase shares of common stock.

S-1/A filing: Ensysce Biosciences, Inc. is offering up to 2,285,714 shares of common stock and Series A-1 warrants to purchase up to 2,285,714 shares of common stock and Series A-2 warrants to purchase up to 2,285,714 shares of common stock, or pre-funded warrants to purchase shares of common stock and common warrants to purchase shares of common stock.

S-1 filing: This is an S-1 filing for a clinical stage pharmaceutical company seeking to develop innovative solutions for severe pain relief while reducing the potential for opioid misuse, abuse and overdose.

8-K filing: Stock split 1-for-12 | Outstanding: 2,950,372 → 245,864

10-K filing | 15.4M shares outstanding

S-3/A filing: This S-3/A filing relates to the issuance and resale of up to 2,272,094 shares of common stock, including shares issuable upon conversion of notes and exercise of warrants.

8-K filing: Ensysce Biosciences, Inc. completed a registered direct offering of 3,571,431 shares of common stock at $0.84 per share, resulting in gross proceeds of approximately $3.0 million, and issued warrants to purchase up to 3,571,431 additional shares. ($3.0M proceeds)

S-3 filing: This S-3 filing is for the issuance and resale of up to 2,272,094 shares of common stock, including shares issuable upon conversion of convertible notes, exercise of warrants issued under the GEM Agreement, and exercise of investor warrants.

S-3 filing: Ensysce Biosciences, Inc. is offering and selling up to $75,000,000 in the aggregate of common stock, preferred stock, debt securities, and subscription rights from time to time in one or more offerings.

S-3 filing: This is an S-3 filing for the issuance and resale of up to 5,522,094 shares of common stock, consisting of shares issuable upon conversion of convertible notes, exercise of warrants, and payment of a commitment fee.

8-K filing: Ensysce Biosciences, Inc. entered into an underwriting agreement with Lake Street Capital Management, LLC for a public offering of 2,280,000 shares of common stock, pre-funded warrants to purchase 620,000 shares, and warrants to purchase 5,800,000 shares of common stock, with an option for the underwriter to purchase additional shares and warrants. ($4.1M proceeds)

S-1/A filing: Ensysce Biosciences, Inc. is offering 4,432,624 shares of common stock at an assumed price of $2.82 per share and accompanying warrant. Each share of common stock or pre-funded warrant is being offered together with a five-year warrant to purchase two shares of our common stock.

S-1/A filing: Ensysce Biosciences, Inc. is offering 4,432,624 shares of common stock at an assumed price of $2.82 per share, along with pre-funded warrants and accompanying warrants. The company intends to use the net proceeds to further the clinical development of its product candidates, and for working capital and other general corporate purposes.

S-1/A filing: This S-1/A filing relates to an offering of common stock and pre-funded warrants, along with accompanying Series A and Series B warrants.

S-1/A filing: Ensysce Biosciences, Inc. is offering 5,274,261 shares of common stock (assuming a combined public offering price of $2.37 per share and accompanying warrants (the last reported sale price of our common stock on Nasdaq on November 14, 2022)) and pre-funded warrants each to purchase one share of our common stock at an exercise price of $0.0001, which we refer to as pre-funded warrants.

10-Q filing | 2.8M shares outstanding

S-1 filing: Ensysce Biosciences, Inc. is filing an S-1 form to register the offering of common stock, pre-funded warrants, Series A warrants, and Series B warrants.

8-K filing: Stock split 1-for-20 | Outstanding: 33,988,783 → 1,699,439

8-K filing: Ensysce Biosciences, Inc. entered into a Letter Agreement reducing the Conversion Price for the remaining balance of the Company's outstanding 2021 Senior Secured Convertible Notes from $0.35 to $0.23 for the period from September 20, 2022 until September 30, 2022; the 2021 Senior Secured Convertible Notes remain due and payable on October 10, 2022.

S-3 filing: This S-3 filing relates to the issuance and resale of up to 4,983,475 shares of common stock, including shares issuable upon conversion of secured convertible promissory notes and exercise of warrants.

10-Q filing | 34.0M shares outstanding

8-K filing: Ensysce Biosciences, Inc. completed a second closing under a Securities Purchase Agreement on August 8, 2022, issuing senior secured convertible promissory notes in the aggregate principal amount of $4.24 million for an aggregate purchase price of $4 million and warrants to purchase 4,667,890 shares of common stock.

8-K filing: Ensysce Biosciences issued senior secured convertible promissory notes and warrants to purchase common stock to institutional investors. The notes and warrants were amended to include an Issuable Maximum of 7,106,055 shares and to restate the definition of 'Floor Price' to include adjustments for share splits. ($8.0M proceeds)

S-3 filing: This prospectus relates to the issuance and resale of up to an aggregate of 39,298,447 shares of common stock, consisting of shares issuable upon conversion of notes and exercise of warrants.

8-K filing: Ensysce Biosciences, Inc. entered into a Securities Purchase Agreement for an aggregate financing of $8.0 million with institutional investors, issuing senior secured convertible promissory notes and warrants to purchase common stock.

10-Q filing | 34.6M shares outstanding

10-K filing | 29.9M shares outstanding

8-K filing: Ensysce Biosciences, Inc. entered into a Securities Purchase Agreement for an aggregate financing of $15 million with institutional investors, with multiple closings and amendments related to the conversion price of notes.

8-K filing: Ensysce Biosciences, Inc. entered into a Letter Agreement amending the Securities Purchase Agreement, allowing noteholders to convert notes at an exercise price of $4.50 per share for a limited period.

10-Q filing | 24.3M shares outstanding

8-K filing: Ensysce Biosciences, Inc. completed a second closing under a Securities Purchase Agreement on November 5, 2021, issuing $10.6 million in senior secured convertible promissory notes and warrants to purchase 722,317 shares of common stock to institutional investors.

S-1/A filing: This is an S-1/A filing for Ensysce Biosciences, Inc. regarding the offering of shares of common stock by selling securityholders, including shares issuable upon conversion of investor notes and exercise of investor warrants.

S-1 filing: The filing is an S-1 registration statement for Ensysce Biosciences, Inc. registering 14,000,000 shares of common stock for resale by selling securityholders, consisting of shares issuable upon conversion of Investor Notes and exercise of Investor Warrants.

8-K filing: Ensysce Biosciences, Inc. entered into a Securities Purchase Agreement for $15 million with institutional investors, issuing notes and warrants in two closings.

S-1/A filing: This S-1/A filing relates to the issuance of common stock upon exercise of warrants and the resale of common stock and warrants by selling securityholders.

10-Q filing | 24.3M shares outstanding

S-1 filing: This is an S-1 filing for Ensysce Biosciences, Inc. involving the issuance and resale of common stock and warrants.

10-Q filing | 6.2M shares outstanding

10-K filing | 6.2M shares outstanding

8-K filing: Leisure Acquisition Corp. entered into a merger agreement with Ensysce Biosciences, Inc., and issued 566,288 private placement warrants to GTWY Holdings in connection with the conversion of a promissory note.

10-Q filing | 6.3M shares outstanding

10-Q filing | 6.3M shares outstanding

10-Q filing | 7.0M shares outstanding

10-K filing | 6.4M shares outstanding

8-K filing: Leisure Acquisition Corp. entered into an agreement and plan of merger with GTWY Holdings Limited, relating to a proposed business combination transaction. ($30.0M proceeds)